Predicting response to HER2 kinase inhibition
نویسندگان
چکیده
منابع مشابه
Predicting response to HER2 kinase inhibition
Comment on: Takagi S, Banno H, Hayashi A, Tamura T, Ishikawa T, Ohta Y. HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285. Oncoscience. 2014; 1:196-204.
متن کاملAntibody Response to Human Extracellular HER2 Subdomain Proteins in Mice
Background: In addition to passive immunotherapy using anti-HER2 monoclonal antibodies, active immunotherapy via HER2 targeting is an interesting approach to inducing specific anti-tumor immune responses. We have recently reported the immunogenicity of HER2 subdomains following DNA immunization and HER2 protein boosting. In the present study, we evaluated the immunogenicity of different HER2 ex...
متن کاملHER2 inhibition: from discovery to clinical practice.
In this issue of Clinical Cancer Research, Buzdar et al. (1) report on the success of trastuzumab, a humanized monoclonal antibody against the proto-oncogene HER2 (c-erbB2, HER-2/ neu), when administered with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) and paclitaxel chemotherapy, with high pathologic complete remission rates. These results are consistent with recent data presented b...
متن کاملResistance to HER2-targeted therapy
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug...
متن کاملOvercoming Resistance to HER2 Inhibitors Through State-Specific Kinase Binding
The heterodimeric receptor tyrosine kinase complex formed by HER2 and HER3 can act as an oncogenic driver and is also responsible for rescuing a large number of cancers from a diverse set of targeted therapies. Inhibitors of these proteins, particularly HER2, have dramatically improved patient outcomes in the clinic, but recent studies have demonstrated that stimulating the heterodimeric comple...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncotarget
سال: 2014
ISSN: 1949-2553
DOI: 10.18632/oncotarget.3036